Relmada Therapeutics, Inc. (RLMD)
NASDAQ: RLMD · Real-Time Price · USD
7.24
+0.21 (2.99%)
Apr 28, 2026, 4:00 PM EDT - Market closed

Relmada Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025 FY 2024 FY 2023 FY 2022 FY 2021 2020 - 2016
Period Ending
Apr '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 2020 - 2016
Market Capitalization
75935416125105625
Upgrade
Market Cap Growth
7893.59%2157.41%-87.41%18.63%-83.18%19.93%
Upgrade
Enterprise Value
666340-3818-79537
Upgrade
Last Close Price
7.244.830.524.143.4922.53
Upgrade
PB Ratio
6.144.090.441.460.753.00
Upgrade
P/TBV Ratio
8.784.090.441.460.753.00
Upgrade
Net Debt / Equity Ratio
-1.07-1.07-1.26-1.13-1.06-1.02
Upgrade
Net Debt / EBITDA Ratio
----0.921.69
Upgrade
Net Debt / FCF Ratio
2.032.030.871.871.432.31
Upgrade
Quick Ratio
14.4614.464.367.9011.9414.08
Upgrade
Current Ratio
14.6214.624.458.0012.2614.83
Upgrade
Return on Equity (ROE)
-94.05%-94.05%-132.33%-87.51%-90.07%-80.14%
Upgrade
Return on Assets (ROA)
-50.24%-50.24%-73.14%-51.76%-53.57%-46.01%
Upgrade
Return on Capital Employed (ROCE)
-64.20%-64.20%-236.10%-121.50%-114.80%-60.40%
Upgrade
Earnings Yield
-7.56%-16.20%-509.73%-79.28%-149.50%-20.13%
Upgrade
FCF Yield
-6.03%-12.93%-329.85%-41.46%-98.81%-14.71%
Upgrade
Buyback Yield / Dilution
-30.89%-30.89%-0.21%-1.59%-68.80%-12.56%
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.